Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Neoleukin Therapeutics, Inc. (NLTX : NSDQ)
 
 • Company Description   
Neoleukin Therapeutics Inc. is a biopharmaceutical company. It is engaged in creating next generation immunotherapies using de novo protein design technology. The company's product candidate consists of NL-201 which is in clinical stage. Neoleukin Therapeutics Inc., formerly known as Aquinox Pharmaceuticals Inc., is based in Seattle, United States.

Number of Employees: 91

 
 • Price / Volume Information   
Yesterday's Closing Price: $1.06 Daily Weekly Monthly
20 Day Moving Average: 298,376 shares
Shares Outstanding: 42.50 (millions)
Market Capitalization: $45.05 (millions)
Beta: 1.24
52 Week High: $11.10
52 Week Low: $0.92
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -24.29% -14.73%
12 Week -62.14% -58.38%
Year To Date -78.01% -71.86%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
188 EAST BLAINE STREET SUITE 450
-
SEATTLE,WA 98102
USA
ph: 855-226-6447
fax: 778-331-4486
investors@neoleukin.com http://www.neoleukin.com
 
 • General Corporate Information   
Officers
Jonathan G. Drachman - Chief Executive Officer and President
Robert Ho - Chief Financial Officer
Martin Babler - Director
M. Cantey Boyd - Director
Erin Lavelle - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 64049K104
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/04/22
Share - Related Items
Shares Outstanding: 42.50
Most Recent Split Date: (:1)
Beta: 1.24
Market Capitalization: $45.05 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.30 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-1.23 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/04/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 0.35
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: -3.70%
vs. Previous Quarter: 0.00%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
03/31/22 - -41.08
12/31/21 - -37.71
09/30/21 - -33.62
ROA
03/31/22 - -36.19
12/31/21 - -33.42
09/30/21 - -30.08
Current Ratio
03/31/22 - 17.16
12/31/21 - 16.67
09/30/21 - 17.40
Quick Ratio
03/31/22 - 17.16
12/31/21 - 16.67
09/30/21 - 17.40
Operating Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Net Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Pre-Tax Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Book Value
03/31/22 - 3.06
12/31/21 - 3.37
09/30/21 - 3.65
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - 0.05
12/31/21 - 0.05
09/30/21 - 0.04
 

Powered by Zacks Investment Research ©